Navigation Links
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
Date:6/29/2009

Company Increases Eligibility to Its Patient Assistance Program to 400 Percent of Federal Poverty; as Many as 75 Percent of U.S. Households May Now Qualify for This Program

GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune today announced the expansion of the MedImmune Assistance Program for Synagis(R) (palivizumab) designed to provide the antibody at no cost to qualifying patients who lack health insurance and whose family household income falls within a certain range of the Federal Poverty Level (FPL) guidelines established by the U.S. Department of Health and Human Services (HHS). Synagis is a biologic medicine known as a monoclonal antibody administered monthly to high-risk infants to prevent serious lower respiratory tract infection caused by respiratory syncytial virus (RSV), a leading cause of viral respiratory infection among infants.

Effective July 1, 2009, patients with household income up to 400 percent of the FPL (e.g. a household of four with an income up to $88,200), and without healthcare coverage or medical insurance, may be eligible to receive Synagis at no cost. This marks a significant expansion over the program's previous eligibility ceiling of 250 percent of the FPL (e.g. $55,125 for that same four-member household).

"MedImmune recognizes the rising cost of healthcare and the burden those expenses can have on working families who lack insurance through no fault of their own," said Tony Zook, MedImmune President. "This expansion of the MedImmune Assistance Program makes it possible for as many as 75 percent of U.S. households without health insurance and with eligible infants to apply to receive the established preventive benefits of Synagis as prescribed by their doctor at no cost to the family."

The MedImmune Assistance Program is administered as part of the Synagis Reimbursement Hotline and can be reached by calling 1-877-778-9010. A health care provider can review
'/>"/>

SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
2. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
3. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
4. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
5. MedImmune Expands Scientific and Engineering Leadership
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
9. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
10. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
11. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 article ... surgeries conducted each year on teenagers, quoting a New York City-area plastic surgeon ... plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients and ...
(Date:9/1/2015)... ... 01, 2015 , ... The Capillus82™ has been cleared by ... in adults, announces Miami-based medical device manufacturer, Capillus, LLC. FDA clearance substantiates the ... when used at home to combat hair loss. , “Following the success ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... therapy company, is pleased to announce their partnership with Apex Physical Therapy ... both groups to continue to provide kind, compassionate, and empathetic care to local ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... From ... 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at ... staff included 65 adult counselors, some of whom work for Calvary, and two junior ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
Breaking Medicine News(10 mins):Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... live a happy married life beat stress better than those ... a best stress buster//. ,Popular perception is that single ... that being in a loving relationship makes it easier to ... online edition of Daily Mail. ,Psychologist Dr Roxane ...
... epidemic proportions, forcing changes in many aspects of that ... fleet of ambulances to cope with a sharp rise ... been introduced and new air ambulances will be remodeled ... equipped with heavy-duty stretchers, capable of carrying patients weighing ...
... are discovering that some foods and supplements do have an ... killer- the ‘big C’. At the 233rd national meeting of ... dozen research papers on this topic will be presented. ... show promise for preventing cancer of the esophagus, colon — ...
... to increase libido in women will hit the market soon. This ... by the European Medicines Agency. ,This patch could be ... the male hormone testosterone into the bloodstream. Intrinsa is intended for ... patch is similar to Viagra for men and is said to ...
... was conducted in all mental health units in England ... in mixed wards//. This is much against the government’s ... hospitals. ,The healthcare commission reports that 55% ... bathrooms with the opposite sex. This practice has resulted ...
... A combination of AZT, lamivudine, and nevirapine (AZT/3TC/NVP) taken ... month after delivery resulted in significantly reduced HIV levels ... found in the breast milk of women who were ... (Drug Resource Enhancement Against AIDS and Malnutrition) in Mozambique ...
Cached Medicine News:Health News:Emboldened Warriors-Cancer Fighting Foods 2Health News:Emboldened Warriors-Cancer Fighting Foods 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4
(Date:9/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... response to the Patent Trial and Appeals Board (PTAB) ... review (IPR), filed by a unit of Boston Scientific ... Patent No. 8,359,102 (the ,102 patent). The ,102 patent is ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta Medical ... Radiography (CR) system, designed to deliver enterprise level imaging ... the same Control Station as the Konica Minolta AeroDR ... an upgrade path from CR to DR. The SIGMA ... help improve workflow with unparalleled reliability and high capacity ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2
... March 21, 2008, HOUSTON, March 3 ... new policies, a national alliance of,scientists, public health ... on a series of proposals designed to eliminate,continued ... of the four year initiative, Eliminating Disparities in,Clinical ...
... Significant Pain Relief with the 2.5 ... and 5 mg Doses Compared to ... (Nasdaq: ALXA ) announced today positive top-line,results from its ... patients with migraine headache. Migraine is a debilitating,yet common neurological ...
Cached Medicine Technology:EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations 2Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 2Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 3Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 4Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 5Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 6Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 7Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: